| Popis: |
We have developed a technology platform to produce anti-viral particles that block infection by broad classes of respiratory, and other, viruses. The anti-viral particles are composed of liposomes with surface-attached glycan receptors designed so that they mimic the natural human viral receptors and strongly adhere to the virus. On this program, one anti-viral particle designed to counter human-adapted influenza A viruses and another to counter respiratory syncytial (RSV) were produced. Receptor-bearing liposomes were demonstrated to bind to virus with high affinity, block viral infection of cells in culture, and improve survival of animals infected with a lethal dose of virus. In addition we have worked toward production of an aerosolized form that can be delivered to the human respiratory tract to prevent the spread of virus during an outbreak or to treat infected individuals. |
